AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29485066
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment of 35 Gy in 15 fractions within 3 weeks (not explicitly detailed in the abstract).
Trial: 29486723
Drug: Pembrolizumab (PD-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (PD-1 immunotherapy)
Trial: 29486723
Drug: Chemokine and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemokine and immunosuppressive molecule expression profiles
Trial: 29486869
Drug: CORT (cortisol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT (cortisol administration)
Trial: 29486918
Drug: Selective internal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective internal radiation therapy (SIRT)
Trial: 29486918
Drug: Selective internal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective internal radiation therapy (SIRT) followed by surgery
Trial: 29487070
Drug: Anti-CD22 moxetumomab
RxNorm normalized name: Allogenic engineered T cells expressing anti-CD22 CAR UCART22
DrugBank: UCART22 (DB17466)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-CD22 moxetumomab pasudotox (50 µg/kg every other day for 3 doses in 4-week cycles)
Trial: 29487070
Drug: Anti-CD22 moxetumomab
RxNorm normalized name: Allogenic engineered T cells expressing anti-CD22 CAR UCART22
DrugBank: UCART22 (DB17466)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-CD22 moxetumomab pasudotox (50 µg/kg)
Trial: 29487219
Drug: Selinexor (65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor (65 mg/m, twice-a-week dosing)
Trial: 29487221
Drug: Ablation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablation therapy after six cycles of chemotherapy
Trial: 29487556
Drug: Long-term pain
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term pain treatment
Trial: 29487697
Drug: 5-fluorouracil- and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil- and irinotecan-based chemotherapy regimens (FOLFIRI or FOLFOXIRI) plus bevacizumab
Trial: 29487870
Drug: Radon water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radon water therapy
Trial: 29487870
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no radon water therapy)
Trial: 29488303
Drug: Glasdegib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glasdegib (100 mg) alone
Trial: 29488303
Drug: Glasdegib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glasdegib (100 mg) following rifampin (600 mg) pre-treatment
Trial: 29489073
Drug: Atomoxetine (pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (pharmacotherapy for cannabis dependence)
Trial: 29489559
Drug: Structured breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured breast implants
Trial: 29490682
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of Tranexamic Acid (TXA)
Trial: 29490682
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g of Tranexamic Acid (TXA)
Trial: 29490680
Drug: BESMILE-HF program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BESMILE-HF program plus usual medications
Trial: 29490690
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TA) 0.5 g
Trial: 29490690
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TA) 1 g
Trial: 29490690
Drug: TA (0-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TA (0-2 g) in H patients
Trial: 29490924
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of antiphospholipid antibodies (APAs)
Trial: 29491412
Drug: BI 894999
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 894999 (novel BET bromodomain inhibitor)
Trial: 29491412
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of BI 894999 and CDK9 inhibitors
Trial: 29497534
Drug: Intravenous IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous IgM immunoglobulin therapy (IVIG group)
Trial: 29497535
Drug: High-dose norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose norepinephrine (≥ 416 μg/kg/week)
Trial: 29497535
Drug: Low-dose norepinephrine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose norepinephrine (not specified)
Trial: 29498038
Drug: Dupilumab (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab (subcutaneous 300 mg weekly)
Trial: 29498742
Drug: ATV/r monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATV/r monotherapy (300/100 mg)
Trial: 29498742
Drug: ATV/r triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATV/r triple therapy (300/100 mg + 2 NRTIs)
Trial: 29498742
Drug: Both ATV/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both ATV/r monotherapy and ATV/r triple therapy
Trial: 29498742
Drug: ATV/r monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATV/r monotherapy
Trial: 29499622
Drug: Stress ulcer
RxNorm normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Stress ulcer prophylaxis (SUP) using acid-suppression drugs
Trial: 29499622
Drug: SUP (acid-suppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUP (acid-suppression drugs)
Trial: 29499622
Drug: Hemostatic drugs
RxNorm normalized name: collagen hemostat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemostatic drugs
Trial: 29499662
Drug: Sorafenib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib at 800 mg/day
Trial: 29499740
Drug: Low-dose transdermal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose transdermal hydrogel MSCs (3 × 10)
Trial: 29499753
Drug: OMPSQ-G (Orebro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMPSQ-G (Orebro musculoskeletal pain screening questionnaire - German version)
Trial: 29499753
Drug: OMPSQ-G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMPSQ-G
Trial: 29500160
Drug: Testosterone injections
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone injections and therapist-assisted progressive resistance training for 20 weeks
Trial: 29500160
Drug: Testosterone injections
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone injections for 20 weeks without physical exercise
Trial: 29500160
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections for 20 weeks combined with 16 weeks of progressive strength training
Trial: 29500160
Drug: Testosterone injections
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone injections for 20 weeks combined with 16 weeks of progressive strength training
Trial: 29500160
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections without physical exercise for 20 weeks
Trial: 29500162
Drug: Community Health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community Health Extension Workers (CHEWs) providing contraceptive subdermal implants
Trial: 29500162
Drug: Nurses and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurses and midwives providing contraceptive subdermal implants
Trial: 29500572
Drug: Ciprofloxacin (CIP)
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (CIP) 750 mg prophylaxis
Trial: 29500837
Drug: Soft tissue
RxNorm normalized name: INSULIN DETEMIR 14.2 mg in 1 mL SOFT TISSUE IMPLANT [Levemir]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft tissue grafting or implant surgery
Trial: 29500837
Drug: Pain pill
RxNorm normalized name: papain Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain pill use
Trial: 29501599
Drug: Deep healing
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep healing (combination of transmural and mucosal healing)
Trial: 29502304
Drug: Insulin dosing
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin dosing errors (lay-users)
Trial: 29502304
Drug: Insulin dosing
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin dosing errors (study personnel)
Trial: 29504483
Drug: sTMS (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sTMS (four pulses twice daily)
Trial: 29506523
Drug: RAAS inhibition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAAS inhibition treatment
Trial: 29506984
Drug: LDL-C <100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C <100 mg/dL
Trial: 29506988
Drug: Cetuximab in
RxNorm normalized name: cetuximab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab in combination with FOLFIRI
Trial: 29507070
Drug: Intravenous ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ganciclovir therapy; specific dosage and duration not mentioned.
Trial: 29507077
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin with cyclophosphamide, doxorubicin, and prednisone (BV+CHP; 6 cycles, then up to 10 cycles of brentuximab vedotin monotherapy)
Trial: 29507099
Drug: 24-hour urinary
RxNorm normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour urinary sodium excretion (118.7 mmol)
Trial: 29507732
Drug: Occupational multicomponent
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational multicomponent rehabilitation including physical exercise and cognitive behavioral therapy (ACT) for either 8 or 17 full days.
Trial: 29507971
Drug: Grazoprevir (GZR),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grazoprevir (GZR), 100 mg, and Elbasvir (EBR), 50 mg, immediately before transplantation; continued GZR-EBR for 12 weeks after transplantation for genotype 1 infection, and added Sofosbuvir, 400 mg, for genotype 2 or 3 infection for 12 weeks of triple therapy.
Trial: 29509546
Drug: PARP-1 PET
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PARP-1 PET imaging agent
Trial: 29509764
Drug: Pharmacological therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological therapies (aspirin, β-blockers, statins)
Trial: 29509992
Drug: Eplerenone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (25 mg daily for 1 week followed by 50 mg daily for 23 weeks)
Trial: 29510735
Drug: Pain-CBT (eight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain-CBT (eight weekly 2-h group sessions with home exercises and readings)
Trial: 29510739
Drug: Durvalumab therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab therapy
Trial: 29511132
Drug: OPB-111077, 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPB-111077, 250 mg QD (maximum tolerated dose)
Trial: 29511132
Drug: OPB-111077, 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPB-111077, 250 mg QD
Trial: 29512061
Drug: Avelumab (immunotherapy)
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab (immunotherapy)
Trial: 29514175
Drug: Low antituberculosis
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low antituberculosis drug concentrations
Trial: 29514256
Drug: Ombrabulin (15.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ombrabulin (15.5 mg/m2), Docetaxel (60 mg/m2), Cisplatin (75 mg/m2)
Trial: 29514256
Drug: Ombrabulin (15.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ombrabulin (15.5 mg/m2), Docetaxel (60 mg/m2), Cisplatin (75 mg/m2) with prophylactic G-CSF
Trial: 29514256
Drug: Docetaxel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (60 mg/m2) monotherapy
Trial: 29514677
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) combined with Task-Oriented Balance Training (TOBT)
Trial: 29514815
Drug: Calgranulin-C (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calgranulin-C (0.75 µg/g)
Trial: 29514815
Drug: Calprotectin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calprotectin (50 µg/g)
Trial: 29514815
Drug: Calprotectin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calprotectin (400 µg/g)
Trial: 29515114
Drug: Momelotinib (MMB;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Momelotinib (MMB; JAK1/2 inhibitor)
Trial: 29515514
Drug: Progressive abduction
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive abduction loading therapy with horizontal-plane viscous resistance
Trial: 29515514
Drug: Progressive abduction
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive abduction loading therapy without horizontal-plane viscous resistance
Trial: 29517567
Drug: Patient e-learning
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient e-learning program, brief advice, educational pamphlet, tobacco quitline referral, letter to the primary care physician, and pharmacotherapy
Trial: 29517567
Drug: Amount spent
RxNorm normalized name: spelt seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amount spent on cigarettes weekly at baseline (per $10 increase)
Trial: 29518185
Drug: Microbial diversity
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microbial diversity after induction and reinduction phases of chemotherapy
Trial: 29518553
Drug: Nivolumab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (240 mg every 2 weeks) plus Crizotinib (250 mg twice daily)
Trial: 29519282
Drug: Manual chest
RxNorm normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual chest compression, electric defibrillation, or epinephrine ≤ 4 mg
Trial: 29519282
Drug: Age <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age < 65 years, witnessed CPR, manual chest compression, electric defibrillation, or epinephrine ≤ 4 mg
Trial: 29519282
Drug: Total adrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total adrenaline ≤ 4 mg
Trial: 29519811
Drug: High-sensitivity troponin
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sensitivity troponin I (hsTnI) concentrations measured using a single-molecule counting assay (99th percentile, 6 ng/L)
Trial: 29519879
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for retinopathy of prematurity (ROP)
Trial: 29519879
Drug: Screening of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening of infants with a GA≤34 weeks or a BW<1700 g
Trial: 29519879
Drug: Independent risk
RxNorm normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Independent risk factors for severe ROP in infants with a BW≤1500 g
Trial: 29519879
Drug: Treatment criteria
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment criteria
Trial: 29523153
Drug: Extracorporeal life
RxNorm normalized name: Life-O-Gen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extracorporeal life support (ECLS) treatment
Trial: 29523153
Drug: ECLS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECLS treatment
Trial: 29523169
Drug: Mobile application
RxNorm normalized name: Mahana IBS CBT Mobile Application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile application (App My eReport France®) introduced by a neurologist to report adverse drug reactions (ADR).
Trial: 29523171
Drug: Umbilical cord
RxNorm normalized name: Sus Scrofa Umbilical Cord
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umbilical cord mesenchymal stem cells (UCMSC) intravenous infusions, 7 infusions of 20 × 10^6 cells each.
Trial: 29523171
Drug: UCMSC intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UCMSC intravenous infusions
Trial: 29525724
Drug: Conservative strategy
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative strategy (medical treatment and coronary angiogram only if persistent clinical instability)
Trial: 29525775
Drug: Individualised, supervised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised, supervised exercise (six weekly sessions)
Trial: 29527010
Drug: Veliparib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib (200 mg BID) plus FOLFIRI (without 5-fluorouracil bolus)
Trial: 29527010
Drug: Veliparib (10-270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib (10-270 mg BID, days 1-5, 15-19) and FOLFIRI (days 1-3, 15-17)
Trial: 29527350
Drug: mCME V.2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mCME V.2.0 intervention (daily SMS quizzes, readings, online CME links, feedback)
Trial: 29528048
Drug: Biomarker-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomarker-guided treatment shortening
Trial: 29528048
Drug: Standard TB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard TB treatment
Trial: 29529091
Drug: Ramadan fasting
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramadan fasting (RF) with aspirin
Trial: 29529156
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplementation (≥400 µg/d)
Trial: 29530544
Drug: tedizolid phosphate
RxNorm normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tedizolid phosphate 200 mg, once-daily for 7-14 days
Trial: 29530544
Drug: linezolid 600
RxNorm normalized name: linezolid 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linezolid 600 mg, twice-daily for 7-14 days
Trial: 29530544
Drug: tedizolid phosphate
RxNorm normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tedizolid phosphate 200 mg, once-daily
Trial: 29530544
Drug: linezolid 600
RxNorm normalized name: linezolid 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linezolid 600 mg, twice-daily
Trial: 29530667
Drug: Avelumab 10
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab 10 mg/kg intravenously every 2 weeks and axitinib 5 mg orally twice daily
Trial: 29530855
Drug: Doripenem administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doripenem administration during dialysis
Trial: 29530855
Drug: Post-hemodialysis dosing
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-hemodialysis dosing of Doripenem
Trial: 29531651
Drug: Elotuzumab in
RxNorm normalized name: elotuzumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elotuzumab in combination with lenalidomide and dexamethasone (ELd)
Trial: 29531784
Drug: Verinurad (2.5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verinurad (2.5-20 mg) plus allopurinol (300 mg once daily)
Trial: 29531784
Drug: Allopurinol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (300 mg once daily, 600 mg once daily, or 300 mg twice daily)
Trial: 29531839
Drug: None (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: None (control group, did not receive chemotherapy)
Trial: 29532104
Drug: GSK3008348, single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3008348, single doses of 1-3000 mcg administered by nebulisation
Trial: 29532104
Drug: GSK3008348, single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3008348, single doses of 300-3000 mcg administered by nebulisation
Trial: 29532243
Drug: Multimodal healthy
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal healthy bone behaviors (HBB) education including a healthy bones prescription (BoneRx), face-to-face education, and customized educational materials.
Trial: 29533458
Drug: Depatuxizumab mafodotin
RxNorm normalized name: Depatuxizumab mafodotin
DrugBank: Depatuxizumab mafodotin (DB11731)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depatuxizumab mafodotin (depatux-m) at a maximum tolerated dose (MTD) of 3.0 mg/kg.